Literature DB >> 1995540

Secondary external-beam radiotherapy and hyperthermia for local recurrence after 125-iodine implantation in adenocarcinoma of the prostate.

I Kaplan1, D S Kapp, M A Bagshaw.   

Abstract

At Stanford, six patients underwent a course of external radiotherapy after local recurrence following 125-iodine implantation. Four of the six patients also received concomitant hyperthermia. Four patients were initially managed with hormonal manipulation at time of local relapse and subsequently received external beam radiotherapy with or without hyperthermia. The hyperthermia was non-invasively induced using an annular phased array radiative electromagnetic system. Treatment was well tolerated, and none of the patients experienced severe rectal or bladder complications. Three patients are free from disease; one patient experience local-regional recurrence based on biopsy; one recurred in the bladder, was treated with cystoprostatectomy and subsequently succumbed to metastatic disease; and one patient died of presumed metastatic disease. External-beam irradiation with concurrent hyperthermia can be safely delivered to treat locally recurrent prostatic carcinoma after 125-iodine implantation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995540     DOI: 10.1016/0360-3016(91)90068-f

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  2 in total

1.  A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis.

Authors:  Mark T Corkum; Lucas C Mendez; Joseph Chin; David D'Souza; R Gabriel Boldt; Glenn S Bauman
Journal:  Adv Radiat Oncol       Date:  2020-05-12

2.  The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A.

Authors:  Jun Ishibashi; Kikuji Yamashita; Tatsuo Ishikawa; Hiroyoshi Hosokawa; Kaori Sumida; Masaru Nagayama; Seiichiro Kitamura
Journal:  Med Oncol       Date:  2007-10-30       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.